Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lohaus

Showing results (261-270 of 284) with videos related to

Pageof 29
Sort By:
Radiation Oncology (London, England)|May 20, 2026
Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort studySebastian Schäfer, Isabell Seiler, Panagiotis Balermpas, et al.
JAMA Network Open|January 14, 2026
Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer TherapyEsmée L Looman, Stephanie G C Kroeze, Jana Schaule, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2017
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung diseaseS Tanadini-Lang, J Rieber, A R Filippi, et al.
The Pharmacogenomics Journal|June 18, 2020
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
Thrombosis and Haemostasis|August 8, 2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stentsYukinori Harada, Jonathan Michel, Raphaela Lohaus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2018
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapyStefan Schmidt, Annett Linge, Alex Zwanenburg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 11, 2026
A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)Bouchra Tawk, Gordana Halec, Katrin Rein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2016
Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROGAnnett Linge, Steffen Löck, Volker Gudziol, et al.
Cancers|June 24, 2022
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORTShivaprasad Patil, Annett Linge, Hannah Hiepe, et al.
Clinical and Translational Radiation Oncology|March 19, 2026
Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort studySebastian Schäfer, Isabell Seiler, Lena Kästner, et al.
Pageof 29

Showing results (261-270 of 284) with videos related to

Sort By:
Pageof 29
Radiation Oncology (London, England)|May 20, 2026
Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort studySebastian Schäfer, Isabell Seiler, Panagiotis Balermpas, et al.
JAMA Network Open|January 14, 2026
Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer TherapyEsmée L Looman, Stephanie G C Kroeze, Jana Schaule, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2017
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung diseaseS Tanadini-Lang, J Rieber, A R Filippi, et al.
The Pharmacogenomics Journal|June 18, 2020
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
Thrombosis and Haemostasis|August 8, 2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stentsYukinori Harada, Jonathan Michel, Raphaela Lohaus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2018
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapyStefan Schmidt, Annett Linge, Alex Zwanenburg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 11, 2026
A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)Bouchra Tawk, Gordana Halec, Katrin Rein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2016
Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROGAnnett Linge, Steffen Löck, Volker Gudziol, et al.
Cancers|June 24, 2022
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORTShivaprasad Patil, Annett Linge, Hannah Hiepe, et al.
Clinical and Translational Radiation Oncology|March 19, 2026
Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort studySebastian Schäfer, Isabell Seiler, Lena Kästner, et al.
Pageof 29